Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic ...

There are many problems with the plan. For instance, it ignores the fact that generic drugs, which make up 90% of ...

The pharmaceutical industry bankrolls ostensibly independent nonprofit organizations to push industry talking points in ...

For pharma, an industry in which gross margins are among the highest ... Companies responded by setting up complex offshore structures to house intellectual property and book profits in low-tax ...

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

Even more recently, AbbVie has joined the list of big ... business fundamentals analyst at GlobalData, said, “Advancements in ADCs could potentially spur biosimilar competition; however, the ...

What makes rare disease work challenging for big pharma companies is that many of the assumptions about the business of pharma no longer apply. “It's a different business model, if you will ...

Europe’s pharma ... business leaders and their companies. But the “America first” protectionist approach favoured by the current administration in Washington will pass. And when it does Big ...

At the national level, the NCPA coordinates with other Big Pharma-funded groups, notably Pharmacists United for Truth and Transparency and the American Pharmacists Association, to promote PBM ...